公开(公告)号：US09834539B2

公开(公告)日：2017-12-05

申请号：US14858167

申请日：2015-09-18

Applicant: Forma Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04

CPC classification number: C07D401/12 ,  A61K31/47 ,  C07D401/14 ,  C07D471/04

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US09771349B2

公开(公告)日：2017-09-26

申请号：US14858170

申请日：2015-09-18

Applicant: Forma Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  A61K31/4704 ,  C07D413/14 ,  C07D401/14 ,  C07D417/14 ,  C07D405/14

CPC classification number: C07D401/12 ,  A61K31/4704 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

公开(公告)号：US09630922B2

公开(公告)日：2017-04-25

申请号：US15130613

申请日：2016-04-15

Applicant: Forma Therapeutics, Inc.

Inventor： Pui Yee Ng ,  Heather Davis ,  Kenneth W. Bair ,  David S. Millan ,  Aleksandra Rudnitskaya ,  Xiaozhang Zheng ,  Bingsong Han ,  Nicholas Barczak ,  David R. Lancia, Jr.

IPC: C07D221/20 ,  C07D403/04 ,  C07D209/96 ,  C07D401/04 ,  C07D417/06 ,  C07D519/00 ,  C07D401/06 ,  C07D413/06 ,  C07D405/04 ,  C07D471/04 ,  C07D497/10 ,  C07D491/107 ,  C07D405/06 ,  C07D403/06 ,  C07D405/10

CPC classification number: C07D209/96 ,  C07D221/20 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D491/107 ,  C07D497/10 ,  C07D519/00

Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

公开(公告)号：US20140163222A1

公开(公告)日：2014-06-12

申请号：US13949712

申请日：2013-07-24

Applicant: Forma Therapeutics, Inc.

Inventor： KRISHNA MURTHI ,  REBECCA CASAUBON ,  ARTHUR F. KLUGE ,  CHASE SMITH ,  JOACHIM VOGT

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06

Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.

公开(公告)号：US20250082628A1

公开(公告)日：2025-03-13

申请号：US18611335

申请日：2024-03-20

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Susan Ashwell ,  Blythe Thomson ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/00

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US20230381151A1

公开(公告)日：2023-11-30

申请号：US18087774

申请日：2022-12-22

Applicant: Forma Therapeutics, Inc.

Inventor： Anna ERICSSON ,  Neal GREEN ,  Gary GUSTAFSON ,  Bingsong HAN ,  David R. Lancia, JR. ,  Lorna MITCHELL ,  David RICHARD ,  Tatiana SHELEKHIN ,  Chase C. SMITH ,  Zhongguo WANG ,  Xiaozhang ZHENG

IPC: A61K31/436 ,  A61P7/06 ,  A61K9/00 ,  C07D487/04 ,  C07D491/056

CPC classification number: A61K31/436 ,  A61P7/06 ,  A61K9/0053 ,  C07D487/04 ,  C07D491/056

Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

公开(公告)号：US11649242B2

公开(公告)日：2023-05-16

申请号：US17239364

申请日：2021-04-23

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  Bingsong Han ,  David R. Lancia, Jr. ,  Lorna Mitchell ,  David Richard ,  Tatiana Shelekhin ,  Chase C. Smith ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D487/04 ,  C07D519/00 ,  A61P7/00 ,  A61K9/00 ,  A61K31/407

CPC classification number: C07D487/04 ,  A61K9/0053 ,  A61K31/407 ,  A61P7/00 ,  C07D519/00

Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

公开(公告)号：US20230101121A1

公开(公告)日：2023-03-30

申请号：US17986414

申请日：2022-11-14

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/02 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

公开(公告)号：US11576906B2

公开(公告)日：2023-02-14

申请号：US16414505

申请日：2019-05-16

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/00 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/7068

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

公开(公告)号：US20220378756A1

公开(公告)日：2022-12-01

申请号：US17761795

申请日：2020-09-18

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Sanjeev Forsyth ,  Neal Green ,  Gary Gustafson ,  Patrick F. Kelly ,  David R. Lancia, JR. ,  Gary Marshall ,  Lorna Mitchell ,  Madhu Mondal ,  Maria Ribadeneira ,  David Richard ,  Patricia Schroeder ,  Zhongguo Wang

IPC: A61K31/436 ,  A61K9/48 ,  A61K9/00 ,  A61P7/06

Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.